The patent system's ability to keep pace with fast-moving life sciences innovation is the subject of a recent IPWatchdog podcast episode. The conversation features Steve Caltrider, Vice President and Chief Intellectual Property Officer at Dana-Farber Cancer Institute and a former General Patent Counsel at Eli Lilly, giving the discussion a distinctly in-house, practitioner-focused perspective.
According to the source, the episode also delved into patent quality and the role of examination. These are longstanding concerns in the field, but they take on added weight as biomedical research becomes more complex and commercially consequential.
Because the article draws on a single interview, it presents one experienced viewpoint rather than a range of opinions. The source does not indicate any disagreement or alternative positions, so the analysis should be read as a snapshot of one IP leader's outlook rather than a broader consensus.